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Abstract
Approximately 6–8% of patients undergoing percutaneous coronary interventions (PCI) have an indication for long-term 
oral anticoagulation with vitamin K antagonists (VKA) or novel oral anticoagulants due to various conditions. Primary 
PCI with adjunctive pharmacological therapy for ST-elevation myocardial infarction (STEMI) patients on chronic VKA 
treatment carry increased risk of bleeding, however, very few studies are available so far.
We describe a patient, who presented with STEMI and international normalized ratio of 4.5 and discuss possible tre-
atment options.
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Introduction
Approximately 6–8% of patients undergoing percuta-
neous coronary interventions (PCI) have an indication 
for long-term oral anticoagulation (OAC) with vitamin K 
antagonists (VKA) or novel oral anticoagulants (NOAC) 
due to various conditions. Primary PCI with adjunctive 
pharmacological therapy for ST-elevation myocardial in-
farction (STEMI) patients on chronic VKA treatment carry 
increased risk of bleeding, however very few studies are 
available so far.
In an impressive United States (US) registry of 
120,270 STEMI patients treated with primary PCI, 3101 pa-
tients (2.6%) were on chronic VKA treatment, which was 
associated with a significant increase in in-hospital major 
bleeding risk compared to no VKA therapy. Surprisingly, 
admission international normalized ratio (INR) ≥ 2.0 was 
not associated with an increase in bleeding risk compared 
to INR < 2.0. However, several limitations of this registry 
were raised by the authors, just to mention two of them. 
There were only a small number of patients with INR > 
3.0 (what precluded adequate statistics). Secondly, no in-
formation was available, whether anticoagulation reversing 
agents (vitamin K or fresh frozen plasma) were used after 
admission to hospital [2].
Case report
61-years-old male patient presented with STEMI of inferior 
wall. His previous history included chronic atrial fibrillation 
on warfarin therapy, acute myocardial infarction and arte-
rial hypertension. Since the admission INR in the referring 
477www.journals.viamedica.pl/folia_cardiologica
Artur Dębski et al., STEMI and anticoagulant treatment
hospital was 4.5, 10 mg of vitamin K was administered 
intravenously, with subsequent INR drop to 4.0 and 1.3 
seven hours later at our institution. Additionally, he received 
loading dose (300 mg) of acetylsalicylic acid and half of 
the dosing dose (300 mg) of clopidogrel. Urgent coronary 
angiography via radial artery revealed tight stenosis in the 
mid segment of the right coronary artery (RCA) with the 
presence of intracoronary thrombus, and non-significant 
lesions in the left coronary artery. Primary PCI of the RCA 
with implantation of 3.5 × 28 mm drug eluting stent was 
performed. Good angiographic result with TIMI 3 flow was 
achieved (Figure 1). Since current INR was not known yet 
during primary PCI, 5000 IU of unfractionated heparin was 
administered. Maximal troponin T was 693 ng/L (upper 
normal limit < 14). Echocardiography revealed significantly 
impaired left ventricle systolic function with akinesia of 
inferior wall and apical segments (ejection fraction 33%). 
No in-hospital bleeding was observed. VKA treatment was 
re-started.
Discussion
No specific regimen for anticoagulation approach for such 
type of patients is suggested in 2012 STEMI guidelines of 
the European Society of Cardiology (ESC). 2015 ESC non-
-STEMI (NSTEMI) guidelines indicate some anti-bleeding 
precautions, all of them only with the class C of evidence 
(expert opinion): 1) in patients on VKA unfractionated he-
parin (UFH) if INR value > 2.5 should be avoided; 2) during 
PCI, additional parenteral anticoagulation is recommended, 
irrespective of the timing of the last VKA dose, if INR is 
2.5 or less, and in patients on NOAC, regardless of the 
timing of the last administration of NOAC, add additional 
low-dose parenteral anticoagulation (e.g. enoxaparin 0.5 
mg/kg i.v. or UFH 60 IU/kg; 3) uninterrupted therapeutic 
anticoagulation with VKA or NOAC should be considered 
during the periprocedural phase.
Data from meta-analysis indicate, that radial access 
seems to be obvious [3] for the benefit in mortality and 
major bleeding. Nonetheless, these data should be inter-
preted with caution. As noted by Mahmud et al, individually 
evaluating the 3 major and heavily weighted studies inclu-
ded in this meta-analysis show the lack of a mechanistic 
link between individual patient access site complications, 
bleeding, and mortality [4].
Conclusion
Individual pharmacological approach with favor of bivali-
rudin is advisable in STEMI patients treated with primary 
PCI, who are presenting with significantly increased INR. 
Radial access is preferred.
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Figure 1A–C. Angiography of the right coronary artery (RCA): A. Tight stenosis in the mid RCA with the presence of intracoronary thrombus 
(magnification); B. Balloon angioplasty; C. Final results with TIMI 3 flow
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Streszczenie
Około 6–8% pacjentów poddawanych przezskórnej angioplastyce wieńcowej (PCI) ma wskazania do przewlekłej terapii 
przeciwkrzepliwej antagonistami witaminy K (VKA) lub nowymi lekami antykoagulacyjnymi. Pierwotna PCI u pacjenta 
leczonego dodatkowo z powodu zawału serca z uniesieniem odcinka ST (STEMI), poddanego jednocześnie przewlekłej 
terapii VKA, jest obarczona istotnie zwiększonym ryzykiem krwawienia. Dostępnych jest jednak niewiele badań odno-
szących się do tego ważnego scenariusza klinicznego.
Opisano pacjenta ze STEMI, u którego wyjściowy międzynarodowy współczynnik znormalizowany wynosił 4,5.
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